vida: extract claims from 2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1

- Source: inbox/queue/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 5
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-anhedonia-absent-from-labels-despite-54k-trial-participants-measurement-gap.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: GLP-1 trials enrolled massive populations but lacked validated anhedonia assessment instruments, creating systematic under-detection of psychiatric adverse effects
+confidence: experimental
+source: Washington Post, FDA label review, researcher interviews
+created: 2026-05-08
+title: Anhedonia is absent from all GLP-1 adverse event labels despite 54,000+ trial participants because trials were not designed to measure hedonic outcomes
+agent: vida
+sourced_from: health/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1.md
+scope: structural
+sourcer: Washington Post Health
+supports: ["glp1-anhedonia-measurement-gap-creates-monitoring-blind-spot-for-most-reported-psychiatric-adverse-effect"]
+related: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-anhedonia-measurement-gap-creates-monitoring-blind-spot-for-most-reported-psychiatric-adverse-effect", "glp1-trials-lack-validated-anhedonia-measurement-infrastructure", "fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence"]
+---
+
+# Anhedonia is absent from all GLP-1 adverse event labels despite 54,000+ trial participants because trials were not designed to measure hedonic outcomes
+
+The Washington Post reports that 'the drug has been studied in 54,000+ trial participants' yet 'anhedonia is NOT currently listed as adverse drug reaction or warning in any GLP-1 label.' Doctors interviewed state that 'reports of anhedonia are not widespread' despite researchers now compiling approximately 100 cases. This detection gap exists because clinical trials were designed to measure metabolic and cardiovascular endpoints, not hedonic capacity. The article notes no validated clinical instruments (like SHAPS, Snaith-Hamilton Pleasure Scale) are mentioned in prescribing practice, 'suggesting the field has not yet operationalized this as a monitorable adverse effect.' The systematic measurement gap means anhedonia could be significantly more prevalent than currently documented but remains invisible to both trial surveillance and post-market pharmacovigilance. This represents a structural regulatory oversight where trial design determines what adverse effects can be detected, and psychiatric outcomes were not prioritized in metabolic drug development.

domains/health/glp1-anhedonia-dose-dependent-reversible-weeks-tonic-suppression.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Clinical case series shows anhedonia resolves in most patients within weeks when GLP-1 dose is reduced, with one documented case improving after 15mg→12.5mg tirzepatide reduction
+confidence: experimental
+source: Washington Post, multi-institution researcher compilation of ~100 cases
+created: 2026-05-08
+title: GLP-1-induced anhedonia is dose-dependent and reverses within weeks of dose reduction through tonic dopamine suppression rather than permanent neurological change
+agent: vida
+sourced_from: health/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1.md
+scope: causal
+sourcer: Washington Post Health
+supports: ["glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-low-dose-psychiatric-protocol-prevents-anhedonia-through-ketogenic-pairing"]
+related: ["glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "glp1-cns-effects-circuit-specific-reward-not-neurodegenerative", "glp1-low-dose-psychiatric-protocol-prevents-anhedonia-through-ketogenic-pairing"]
+---
+
+# GLP-1-induced anhedonia is dose-dependent and reverses within weeks of dose reduction through tonic dopamine suppression rather than permanent neurological change
+
+Researchers compiling approximately 100 cases of GLP-1-induced anhedonia report that 'most cases appeared to resolve with dose reduction often as quickly as within a few weeks.' One specific case documented a patient on Zepbound (tirzepatide) who reduced from 15mg to 12.5mg weekly and 'within two weeks reported feeling joy again.' The rapid reversibility timeframe (weeks, not months) combined with dose-response relationship suggests tonic receptor occupancy mechanism rather than permanent neurological adaptation. The proposed mechanism involves GLP-1 receptors in brainstem, lateral septum, and hypothalamus that 'tone down regions of the brain associated with pleasure.' Some persistent cases respond to bupropion (dopamine-enhancing antidepressant), supporting dopaminergic mediation. However, animal evidence is contradictory: one lab found 'chronically muted dopamine responses' while another found 'turbocharged' dopamine signal, indicating the precise mechanism remains unsettled. The clinical reversibility pattern distinguishes this from permanent structural changes and suggests anhedonia results from ongoing pharmacological suppression that lifts when drug exposure decreases.

domains/health/glp1-anhedonia-measurement-gap-creates-monitoring-blind-spot-for-most-reported-psychiatric-adverse-effect.md

@@ -11,9 +11,16 @@ sourced_from: health/2026-05-07-pmc-glp1-psychiatric-systematic-review-2026.md
 scope: structural
 sourcer: Sa et al. (2026)
 supports: ["glp1-trials-lack-validated-anhedonia-measurement-infrastructure"]
-related: ["fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-trials-lack-validated-anhedonia-measurement-infrastructure", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations"]
+related: ["fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-trials-lack-validated-anhedonia-measurement-infrastructure", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-anhedonia-measurement-gap-creates-monitoring-blind-spot-for-most-reported-psychiatric-adverse-effect"]
 ---
 
 # GLP-1 anhedonia measurement gap creates monitoring blind spot for most reported psychiatric adverse effect
 
 A comprehensive 38-study systematic review found that anhedonia data is 'ABSENT' from GLP-1 psychiatric literature despite being the most commonly reported psychiatric adverse effect in clinical practice. The review notes 'emotional blunting mentioned as potential adverse outcome but no incidence data. Anhedonia not characterized as distinct outcome.' This represents a genuine measurement infrastructure gap, not merely a knowledge gap. Standard depression scales (PHQ-9, HAM-D) used in GLP-1 trials do not isolate anhedonia as a distinct construct, and no GLP-1 trial has prospectively measured anhedonia using validated instruments like the Snaith-Hamilton Pleasure Scale. The clinical significance is that the most frequently reported psychiatric adverse effect is invisible to both clinical trials and pharmacovigilance systems. This creates a monitoring blind spot where patient-reported anhedonia cannot be systematically tracked, quantified, or correlated with dose, duration, or patient characteristics. The review's clinical recommendations include monthly psychiatric monitoring but provide no guidance on anhedonia assessment because no validated protocol exists.
+
+
+## Supporting Evidence
+
+**Source:** Washington Post 2026-04-16, FDA label review
+
+54,000+ trial participants studied but anhedonia not listed on any GLP-1 label. Article notes no validated clinical instruments (SHAPS) mentioned in prescribing practice, 'suggesting the field has not yet operationalized this as a monitorable adverse effect.'

domains/health/glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible.md

@@ -31,3 +31,10 @@ Systematic review of 80 RCTs (107,860 participants) finds 'direct evidence linki
 **Source:** Dr. Bosworth/Albright cohorts via Osmind
 
 Clinical evidence from ~100-patient cohorts shows 0.6mg weekly tirzepatide (quarter standard dose) produces no emotional blunting when paired with ketogenic diet. Supports dose-dependence mechanism and suggests ketogenic pairing may modulate anhedonic threshold.
+
+
+## Supporting Evidence
+
+**Source:** Washington Post 2026-04-16, multi-institution ~100 case compilation
+
+Washington Post documents specific case: patient reduced tirzepatide 15mg→12.5mg weekly, reported feeling joy again within two weeks. Researchers report 'most cases appeared to resolve with dose reduction often as quickly as within a few weeks.' Rapid reversibility timeframe (weeks) supports tonic suppression mechanism.

domains/health/glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant.md

@@ -10,26 +10,18 @@ agent: vida
 sourced_from: health/2026-05-05-ozempic-personality-anhedonia-glp1-dopamine.md
 scope: causal
 sourcer: Multiple (Washington Post, KTLA, Washington Times)
-challenges:
+challenges: ["medical-care-explains-only-10-20-percent-of-health-outcomes-because-behavioral-social-and-genetic-factors-dominate-as-four-independent-methodologies-confirm"]
-- medical-care-explains-only-10-20-percent-of-health-outcomes-because-behavioral-social-and-genetic-factors-dominate-as-four-independent-methodologies-confirm
+related: ["modernization-dismantles-family-and-community-structures-replacing-them-with-market-and-state-relationships-that-increase-individual-freedom-but-erode-psychosocial-foundations-of-wellbeing", "modernization dismantles family and community structures replacing them with market and state relationships that increase individual freedom but erode psychosocial foundations of wellbeing", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "food-noise-quiet-narrative-reframes-glp1-anhedonia-as-liberation", "glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure"]
-related:
+supports: ["Cultural narrative framing 'food noise quiet' as liberation delays recognition of GLP-1 dopamine suppression harm", "GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS", "GLP-1 anhedonia measurement gap creates monitoring blind spot for most reported psychiatric adverse effect"]
-- modernization-dismantles-family-and-community-structures-replacing-them-with-market-and-state-relationships-that-increase-individual-freedom-but-erode-psychosocial-foundations-of-wellbeing
+reweave_edges: ["Cultural narrative framing 'food noise quiet' as liberation delays recognition of GLP-1 dopamine suppression harm|supports|2026-05-06", "GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS|supports|2026-05-07", "GLP-1 anhedonia measurement gap creates monitoring blind spot for most reported psychiatric adverse effect|supports|2026-05-08"]
-- modernization dismantles family and community structures replacing them with market and state relationships that increase individual freedom but erode psychosocial foundations of wellbeing
-- medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm
-- glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation
-- hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement
-- glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
-- glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring
-supports:
-- Cultural narrative framing 'food noise quiet' as liberation delays recognition of GLP-1 dopamine suppression harm
-- GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS
-- GLP-1 anhedonia measurement gap creates monitoring blind spot for most reported psychiatric adverse effect
-reweave_edges:
-- Cultural narrative framing 'food noise quiet' as liberation delays recognition of GLP-1 dopamine suppression harm|supports|2026-05-06
-- GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS|supports|2026-05-07
-- GLP-1 anhedonia measurement gap creates monitoring blind spot for most reported psychiatric adverse effect|supports|2026-05-08
 ---
 
 # GLP-1 anhedonia mechanism undermines social engagement and meaning as non-clinical health determinants even while treating metabolic disease
 
 Clinicians are reporting a pattern they call 'Ozempic personality' where GLP-1 patients experience reduced interest not just in food but in social activities, sex, music, and other pleasurable activities. The mechanism is the same VTA dopamine circuit suppression that makes GLP-1 effective for addiction treatment — GLP-1 receptors in brain regions governing mood, motivation, and emotional responses inadvertently affect emotional engagement when altered. Patients describe 'emotional flattening' where they still recognize positive moments but feel less excitement or connection. This creates a paradox: GLP-1 may simultaneously treat metabolic disease (the clinical 10-20% of health determinants) while undermining the motivational substrate for social engagement and meaning (the behavioral/social 80-90%). The mechanism is supported by addiction research showing GLP-1 reduces craving preconsciously, indicating reward processing changes extend beyond food. No quantitative prevalence data exists yet — this is clinical pattern recognition phase with anecdotal reports from clinicians and social media. The FDA removed the suicidal behavior warning from GLP-1 in 2026 and no anhedonia warning exists, suggesting regulatory bodies are not yet tracking this risk.
+
+## Extending Evidence
+
+**Source:** Washington Post 2026-04-16, patient interviews
+
+Documented anhedonia extends beyond food to 'social activities, music, sex, and daily pleasures' — broad emotional blunting affecting all hedonic domains. One patient quote describes life feeling 'meh' across all previously enjoyable activities.

domains/health/glp1-cns-effects-circuit-specific-reward-not-neurodegenerative.md

@@ -10,19 +10,17 @@ agent: vida
 sourced_from: health/2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision.md
 scope: structural
 sourcer: Hartej Gill, University of Toronto
-related:
+related: ["semaglutide-reduces-effort-cost-sensitivity-in-mdd-via-reward-circuit-engagement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "glp1-cns-effects-circuit-specific-reward-not-neurodegenerative", "glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure", "semaglutide-fails-alzheimers-progression-despite-biomarker-effects-distinguishing-metabolic-prevention-from-neurodegeneration-treatment", "glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials"]
-- semaglutide-reduces-effort-cost-sensitivity-in-mdd-via-reward-circuit-engagement
+supports: ["GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration"]
-- glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation
+reweave_edges: ["GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration|supports|2026-05-08"]
-- semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression
-- glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
-- hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement
-- glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant
-supports:
-- GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration
-reweave_edges:
-- GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration|supports|2026-05-08
 ---
 
 # GLP-1 receptor agonists demonstrate circuit-specific CNS effects—efficacy in reward pathways but not neurodegenerative pathways
 
 The Gill MDD trial showing positive effects on effort-based decision-making (reward circuit function) combined with EVOKE/EVOKE-Plus Alzheimer's trial failures establishes a clear pattern: GLP-1 receptor agonists demonstrate efficacy in reward pathway disorders (major depression motivation deficits, alcohol use disorder) but not in neurodegenerative conditions. This circuit specificity maps to GLP-1 receptor distribution—high density in VTA, nucleus accumbens, and hypothalamus (reward/motivation circuits) but limited presence in cortical regions affected by neurodegeneration. The MDD trial's dissociation between failed executive function endpoint and successful effort-cost endpoint within the same study provides within-trial evidence of this specificity. This defines the therapeutic boundary for GLP-1 CNS applications: reward dysregulation conditions are viable targets, neurodegenerative conditions are not. The mechanism is receptor distribution, not general neuroprotection.
+
+## Supporting Evidence
+
+**Source:** Washington Post 2026-04-16, mechanism review
+
+Proposed mechanism: 'GLP-1 receptors in brainstem, lateral septum, and hypothalamus modulate neural pathways for food intake, reward, and energy. GLP-1s tone down regions of the brain associated with pleasure.' Circuit-specific reward suppression rather than global neurodegeneration.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -10,25 +10,10 @@ agent: vida
 sourced_from: health/2026-04-23-glp1-substance-use-disorder-33-trials.md
 scope: causal
 sourcer: PubMed/ClinicalTrials.gov systematic review
-challenges:
+challenges: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm"]
-- medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm
+related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure", "glp1-cns-effects-circuit-specific-reward-not-neurodegenerative"]
-related:
+supports: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery", "GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration"]
-- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation
+reweave_edges: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment|supports|2026-04-24", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery|supports|2026-04-24", "GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration|supports|2026-05-08"]
-- medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm
-- glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation
-- hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement
-- behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions
-- glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population
-- glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients
-- glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
-supports:
-- The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment
-- Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery
-- GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration
-reweave_edges:
-- The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment|supports|2026-04-24
-- Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery|supports|2026-04-24
-- GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration|supports|2026-05-08
 ---
 
 # GLP-1 receptor agonists may address multiple substance use disorders through shared mesolimbic dopamine circuit modulation with 33 clinical trials underway across alcohol opioid nicotine and cocaine use
@@ -173,3 +158,9 @@ Systematic review cites 29% alcohol reduction with dulaglutide and notes 'potent
 **Source:** Psychopharmacology Institute Q1 2026 Review
 
 Psychopharmacology Institute Q1 2026 guidance omits substance use disorder applications entirely, despite JAMA Psychiatry RCT evidence for AUD being available by Q1 2026. This suggests professional society guidance lags clinical evidence by approximately 1 year, creating a gap between published efficacy data and clinical practice recommendations.
+
+## Extending Evidence
+
+**Source:** Washington Post 2026-04-16, researcher interviews
+
+Contradictory animal evidence on dopamine mechanism: one lab found 'chronically muted dopamine responses' while another found 'turbocharged' dopamine signal. Some persistent anhedonia cases treated with bupropion (dopamine-enhancing antidepressant) as compensatory treatment, supporting dopaminergic pathway but revealing mechanistic uncertainty.

inbox/archive/health/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1.md

@@ -7,10 +7,13 @@ date: 2026-04-16
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-08
 priority: high
 tags: [GLP-1, semaglutide, anhedonia, ozempic-personality, dopamine, reward, side-effects, dose-dependence, reversibility]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content